Top Stories
According to Bloomberg, the pharma is trimming its respiratory and immunology sales teams, though some of the staff are expected to be reassigned within the company.
The approval was backed by data from the Phase III VOLGA study showing 49% lower risk of an event-free survival (EFS) event, and 42% lower risk of death.
Integrated analysis finds 89% fewer attacks after lonvo-z treatment in hereditary angioedema (HAE), potentially bolstering the case for long-term efficacy.
The Swiss biotech is developing long-acting respiratory antibodies, while Rezera is focused on oral NLRP3 inhibitors.
The company suggested that decisions on the filings for the oral pyruvate kinase activator are expected in 2027.
Conference News
Statistically significant reductions in food noise scores from baseline were observed in adults taking semaglutide injection within the first month of initiation and through six months in the SIGNAL s...
Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be pr...
REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults w...
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes...
In a post hoc analysis of the phase 3 REDEFINE 1 trial, 67.8% of adults treated with investigational CagriSema 2.4 mg / 2.4 mg were early responders, achieving at least 5% weight loss by week 81Women ...



